Navigation Links
Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
Date:6/1/2011

ANAHEIM, Calif., June 1, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at The Jefferies Global Healthcare Conference to be held June 6-9, 2011 at the Grand Hyatt in New York City.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Thursday, June 9, 2011 at 10:30 a.m. ET.

To listen to the audio web cast of the presentation during or after the event, please visit: www.questcor.com.  The replay will be available for ninety days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling as
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
2. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
3. Lexicon Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
4. Amylin Pharmaceuticals to Present at Goldman Sachs 32nd Annual Global Healthcare Conference and Jefferies Global Life Sciences Conference
5. Avanir Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
6. MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug
7. Watson Acquires Specifar Pharmaceuticals
8. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
9. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
10. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
11. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... UFP Technologies, a producer of innovative ... introduced a custom insulated shipping container to house ... insulated shipper solves the issue of temperature variations ... BioShell is a universal storage container which protects ... shipping. The insulated shipper keeps frozen BioShells within ...
(Date:9/30/2014)... 30, 2014 The International ... a non-profit organization based in Pittsburgh, Pennsylvania, and ... Safety (ACRES), a Massachusetts non-profit charitable organization, ... agreement, setting the stage for multiple collaborative projects. ... research quality and safety through specialized nursing practice ...
(Date:9/29/2014)... the military conflicts in Iraq and Afghanistan, more than ... traumatic brain injury caused by exposure to bomb blasts ... or IEDs. Symptoms of traumatic brain injury can range ... to more severe impairments in memory and cognition. ... recognized the critical importance and complexity of this problem, ...
(Date:9/29/2014)... , Sept. 29, 2014 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that its three Promissory ... Portage, who advanced $ 100,000 each in July 2014 ... their Notes and related Coupons converted into 3,500,001 restricted ... carried 5% coupon. Both the Note and the coupon ...
Breaking Biology Technology:UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3
... Alba Therapeutics Corporation today,announced that its Investigational ... of endogenous insulin production capacity in new-onset,type 1 ... deliberation period,by the U.S. Food and Drug Administration ... study in 2008 while focusing the majority,of its ...
... will review common U.S. laws on research and process labs ... offer practical ... in association with Lab Manager Magazine, will present a Web,conference ... EST. The online conference will review common U.S. federal laws,pertaining ...
... SAN CARLOS, Calif., Sept. 5 NeurogesX, Inc.,(Nasdaq: ... developing novel,pain management therapies, announced today the appointment ... directors. Since May 2006, Mr. Peacock,has been a ... Prior to joining SV Life Sciences, Mr. Peacock ...
Cached Biology Technology:Alba Therapeutics Announces IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001 2Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies 2Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies 3NeurogesX Appoints New Director to the Board 2NeurogesX Appoints New Director to the Board 3
(Date:9/29/2014)... Energy Joint Genome Institute (DOE JGI), a DOE ... 32 new projects have been selected for the ... lakes to Caribbean waters, and from plant root ... in forested watersheds, the CSP 2015 projects portfolio ... be extracted. , "These projects catalyze JGI,s ...
(Date:9/29/2014)... anti-tumour activity in patients with advanced BRAF V600E ... progressed after chemotherapy, according to phase II data ... Spain. , "Reports of lung cancers bearing ... these mutations may be associated with increased sensitivity ... Dr David Planchard, pulmonary oncologist at the Gustav-Roussy ...
(Date:9/29/2014)... is here, and that means beer. And ... cold one, taking that first sip and ... reacted to form compounds that cause an ... why beers get skunky, and what you ... going bad. Learn all about it at ...
Breaking Biology News(10 mins):2015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3
... steps have public officials in your state or community taken ... who are obese has tripled in just 35 years. Local ... it either easy or hard for families to find fresh ... and be physically active. LOCAL GOVERNMENT ACTIONS TO PREVENT CHILDHOOD ...
... at Virginia Tech, Harvard and Drexel finish studying the locomotion ... has a few new ways to increase his own world-breaking ... to maneuver in tight places, or to hover in one ... has researchers wondering if they can create smarter materials that ...
... Zurich, Switzerland, August 18, 2009 / b3c newswire ... that, following the successful completion of key research ... disease has advanced into preclinical development, triggering milestone ... (NASDAQ: BIIB). Neurimmune partnered with Biogen Idec for ...
Cached Biology News:Tackling childhood obesity at the local level -- IOM report releases Sept. 1 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 3Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 2Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 3